Madrigal Pharmaceuticals (MIL:1MDGL) Research & Development: €388.5 Mil (TTM As of Mar. 2026)


MIL:1MDGL Madrigal Pharmaceuticals Inc MIL:1MDGL
8 GF Score
Price €416.00
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals Research & Development?

Madrigal Pharmaceuticals MIL:1MDGL 8 Research & Development is €388.5 Mil as of Mar. 2026. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Madrigal Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was €94.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €388.5 Mil.

Madrigal Pharmaceuticals  (MIL:1MDGL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Madrigal Pharmaceuticals Research & Development Related Terms

Madrigal Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Madrigal Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals Research & Development Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 181.57 231.70 249.75 226.07 331.80

Madrigal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.86 46.89 148.25 99.29 94.02
MIL:1MDGL
8GF Score
Madrigal Pharmaceuticals Inc MIL:1MDGL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €388.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €388.5 Mil mean?
Madrigal Pharmaceuticals (MIL:1MDGL) has a Research & Development of €388.5 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Madrigal Pharmaceuticals and its competitors.
Is Madrigal Pharmaceuticals' Research & Development too high?
Madrigal Pharmaceuticals' current Research & Development is €388.5 Mil. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Research & Development compare to BMRN and ARWR?
Madrigal Pharmaceuticals' Research & Development of €388.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Research & Development is €388.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Research & Development of €388.5 Mil. The current Research & Development is €388.5 Mil. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Research & Development is €388.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Other Exchanges MDGL:USA0JXI:UKYDO1:Germany
Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score

Get the complete analysis for MIL:1MDGL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€416.00
Price